Bionest

Time to Embrace Decentralized Clinical Trials

A clearer roadmap for decentralized clinical trials will enable companies to better plan and more quickly advance their adoption of these strategies, which have the potential of benefiting patients and drug developers alike.

Bionest

Wearables Evolve from Wellness to Clinical Medicine

Wearables – including consumer products like FitBit wristbands and smartwatches – are quickly moving beyond their use as wellness products that track steps and sleep patterns to incorporate serious medical device capabilities and clinical applications.   In September 2018, the Apple Series 4 model smartwatch became the first such product to have its software officially...

Bionest

The Changing World of Medical Marketing

A recent survey published in the Journal of the American Medical Association (JAMA) reported that the medical marketing spend in the United States rose from approximately $17.7 billion in 1997 to just under $30 billion in 2016. The biggest growth came from Direct-to-Consumer (DTC) marketing, which increased from 11.9% to 32% of the total spend....

Bionest

Innovations in Electronic Health Records

Increasingly, hospital and health systems have moved from paper charts to electronic health records (EHRs). EHRs offer ways to streamline clinical workflows, reduce medical errors and increase patient safety, and provide stronger support for clinical decision-making. However, linking such records from different locations for the same patient has proved problematic in many cases, leading to...

Bionest

Steps Toward the Use of Real World Evidence

“Real-world evidence” (RWE) is data on the use and accrued long-term benefits/risks of a drug or device that is gathered outside of a clinical trial — generally after the product has been approved. Clinical trials don’t often reflect the breadth and diversity of patient experience with a particular treatment that can be seen once the...

Bionest

Reinventing Medical Affairs to the Benefit of All

The concept of patient-centric drug development has been a frequent topic of discussion in recent years. Increasingly, companies have moved to adopt practices that create more active, networked relationships and interactions between physicians, patients, advocates and drug developers. The aim of such practices is to better respond to patient and physician needs and concerns, while...

Bionest

See you at ASCO 2016!

It’s nearly June, which means one thing for the Bionest Oncology team:  ASCO is right around the corner.  As we gear up for our time in Chicago, we are taking a look at some of the big topics and anticipated data we expect to see during the conference. The theme of ASCO this year is...

Bionest

“Beyond the Pill” — Part Two: Value-Added Services Offer Benefit to Multiple Audiences

In our first “Beyond the Pill” post, we discussed the increasing move towards patient-centric programs that go past an actual prescription to help build relationships with patients and physicians and facilitate the provision of a number of related services to improve compliance and treatment outcomes and keep patients on drug long-term. The benefit of such...

Bionest

“Beyond the Pill,” Part One: Value-Added Services Increasingly Needed Due to Changing Nature of Therapies

The notion of patient-centricity has gained increasing attention from drug developers and others in recent years, mostly in the area of chronic diseases and those requiring complex therapies. But value-added services, which go beyond simple initiatives addressed to patient compliance and access to therapy, are also gaining increasing attention from a variety of other audiences,...

Bionest

Personalized Cancer Therapies: Time to Take Lessons from “Orphan Drugs”

We recently wrote about rare disease drug development and commercialization, and why such franchises succeed better within small companies or perhaps as stand-alone, independently operating units of larger firms. When the patient population targeted by a particular therapy is small, success depends on a highly patient-centric approach to both drug development and commercialization. One must...